• Mechanism of Action
• Selectively inhibits cyclin-dependent kinase (CDK) 4 and 6, which act downstream of multiple mitogenic signalling pathways to stimulate cell proliferation.

Clinical Use

• • Indication
  • HER2 negative, ER / PR positive advanced or metastatic breast cancer in men or postmenopausal women (in combination with an aromatase inhibitor).
• • Adverse Effects